Pacqué M, Elmets C, Dukuly Z D, Muñoz B, White A T, Taylor H R, Greene B M
Dana Center for Preventive Ophthalmology, Wilmer Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Am J Med. 1991 May;90(5):590-4.
Skin disease is the most common clinically important manifestation of onchocerciasis. Ivermectin, a newly available drug, is well tolerated and effective in Onchocerca volvulus infection. However, little information is available regarding its effect on onchocercal skin disease. The purpose of this study was to examine, in patients with well-characterized onchodermatitis, the effect of a single dose of ivermectin.
Twenty-one persons with severe onchodermatitis were followed over a 6-month period. In order to evaluate the effect of ivermectin on their skin lesions, photographic transparencies were made before treatment and at 3 and 6 months after treatment. These were then evaluated in a blinded fashion.
Following a single dose of 150 micrograms/kg, there was a significant improvement in dermatitis in the first 3 months after treatment. All 14 persons with the worst skin disease showed improvement. The drug had no demonstrable effect on depigmented lesions over the period of observation. Treatment was well tolerated.
Single-dose ivermectin shows promise as the first acceptable treatment for severe onchocercal dermatitis.
皮肤病是盘尾丝虫病临床上最常见的重要表现。伊维菌素是一种新上市的药物，对盘尾丝虫感染耐受性良好且有效。然而，关于其对盘尾丝虫性皮肤病的影响，目前可用信息较少。本研究的目的是在具有明确特征的盘尾丝虫性皮炎患者中，研究单剂量伊维菌素的效果。
21例患有严重盘尾丝虫性皮炎的患者接受了为期6个月的随访。为了评估伊维菌素对其皮肤病变的影响，在治疗前以及治疗后3个月和6个月制作了照片透明片。然后以盲法对这些照片进行评估。
单次服用150微克/千克后，治疗后的前3个月内皮炎有显著改善。所有14例皮肤病最严重的患者均有改善。在观察期内，该药物对色素脱失性病变无明显效果。治疗耐受性良好。
单剂量伊维菌素有望成为严重盘尾丝虫性皮炎的首个可接受的治疗方法。
